Cargando…

Trastuzumab deruxtecan for breast cancer

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	NPS MedicineWise 2022
Materias:	New Drugs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427624/ https://www.ncbi.nlm.nih.gov/pubmed/36110180 http://dx.doi.org/10.18773/austprescr.2022.043

Ejemplares similares

Alpelisib for breast cancer
Publicado: (2022)

Abemaciclib for breast cancer
Publicado: (2020)

Neratinib for breast cancer
Publicado: (2019)

Sacituzumab govitecan for breast cancer
Publicado: (2022)

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
por: Rugo, H.S., et al.
Publicado: (2022)

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
por: Kabraji, Sheheryar, et al.
Publicado: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Two cases of trastuzumab deruxtecan‐induced interstitial lung disease in advanced breast cancer
por: Gocho, Kyoko, et al.
Publicado: (2022)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
por: Guo, Zihan, et al.
Publicado: (2022)

Darolutamide for prostate cancer
Publicado: (2020)

Niraparib for ovarian cancer
Publicado: (2021)

Tisagenlecleucel for B-cell cancers
Publicado: (2019)

Lurbinectedin for small cell lung cancer
Publicado: (2021)

Brigatinib for non-small cell lung cancer
Publicado: (2020)

Lorlatinib for non-small cell lung cancer
Publicado: (2020)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

Entrectinib for non-small cell lung cancer and solid tumours
Publicado: (2020)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer
Publicado: (2022)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
por: Siddiqui, Tasmiyah, et al.
Publicado: (2022)

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
por: Adams, E., et al.
Publicado: (2021)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
por: Mosele, Fernanda, et al.
Publicado: (2023)

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
por: Moss, Nelson S, et al.
Publicado: (2022)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

Dilated cardiomyopathy following trastuzumab chemotherapy
por: Karmakar, Saurabh, et al.
Publicado: (2012)

Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
por: Baba, Tomohisa, et al.
Publicado: (2023)

Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
por: Lang, Yitian, et al.
Publicado: (2022)

Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
por: Matsui, Chiaki, et al.
Publicado: (2023)

Lanadelumab for hereditary angioedema
Publicado: (2022)

Ravulizumab for paroxysmal nocturnal haemoglobinuria
Publicado: (2022)

SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c5fo3b7a35jkl86vvvinlgs936